387 related articles for article (PubMed ID: 9215272)
1. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy.
Tobiume H; Kanzaki S; Hida S; Ono T; Moriwake T; Yamauchi S; Tanaka H; Seino Y
J Clin Endocrinol Metab; 1997 Jul; 82(7):2056-61. PubMed ID: 9215272
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone (GH) treatment of GH-deficient children increases serum levels of insulin-like growth factors (IGFs), IGF-binding protein-3 and -5, and bone alkaline phosphatase isoenzyme.
Ono T; Kanzaki S; Seino Y; Baylink DJ; Mohan S
J Clin Endocrinol Metab; 1996 Jun; 81(6):2111-6. PubMed ID: 8964836
[TBL] [Abstract][Full Text] [Related]
3. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
Magnusson P; Degerblad M; Sääf M; Larsson L; Thorén M
J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
[TBL] [Abstract][Full Text] [Related]
4. Serum free insulin-like growth factor I (IGF-I), total IGF-I, and IGF-binding protein-3 concentrations in normal children and children with growth hormone deficiency.
Kawai N; Kanzaki S; Takano-Watou S; Tada C; Yamanaka Y; Miyata T; Oka M; Seino Y
J Clin Endocrinol Metab; 1999 Jan; 84(1):82-9. PubMed ID: 9920066
[TBL] [Abstract][Full Text] [Related]
5. Serum propeptide and intact molecular osteocalcin in normal children and children with growth hormone (GH) deficiency: a potential marker of bone growth and response to GH therapy.
Kanzaki S; Hosoda K; Moriwake T; Tanaka H; Kubo T; Inoue M; Higuchi J; Yamaji T; Seino Y
J Clin Endocrinol Metab; 1992 Oct; 75(4):1104-9. PubMed ID: 1400878
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
Gonc EN; Kandemir N
Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
[TBL] [Abstract][Full Text] [Related]
7. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children.
Crofton PM; Stirling HF; Schönau E; Kelnar CJ
Clin Endocrinol (Oxf); 1996 Apr; 44(4):385-94. PubMed ID: 8706304
[TBL] [Abstract][Full Text] [Related]
8. The effect of growth hormone treatment on serum bone alkaline phosphatase in growth hormone deficient children.
Korpal-Szczyrska M; Balcerska A
Pediatr Endocrinol Diabetes Metab; 2008; 14(4):211-4. PubMed ID: 19239787
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.
Garnero P; Delmas PD
J Clin Endocrinol Metab; 1993 Oct; 77(4):1046-53. PubMed ID: 8104954
[TBL] [Abstract][Full Text] [Related]
10. Short-term changes in bone formation markers following growth hormone (GH) treatment in short prepubertal children with a broad range of GH secretion.
Andersson B; Swolin-Eide D; Magnusson P; Albertsson-Wikland K
Clin Endocrinol (Oxf); 2015 Jan; 82(1):91-9. PubMed ID: 24818653
[TBL] [Abstract][Full Text] [Related]
11. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment.
Spagnoli A; Branca F; Spadoni GL; Cianfarani S; Pasquino AM; Argirò G; Vitale S; Robins SP; Boscherini B
J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806
[TBL] [Abstract][Full Text] [Related]
12. Renal handling of phosphate can predict height velocity during growth hormone therapy for short children.
Nishiyama S; Ikuta M; Nakamura T; Tomoeda S; Matsuda I
J Clin Endocrinol Metab; 1992 Apr; 74(4):906-9. PubMed ID: 1548358
[TBL] [Abstract][Full Text] [Related]
13. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children.
Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; DiNero G
Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377
[TBL] [Abstract][Full Text] [Related]
14. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years.
Rauchenzauner M; Schmid A; Heinz-Erian P; Kapelari K; Falkensammer G; Griesmacher A; Finkenstedt G; Högler W
J Clin Endocrinol Metab; 2007 Feb; 92(2):443-9. PubMed ID: 17105843
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
Kamp GA; Mul D; Waelkens JJ; Jansen M; Delemarre-van de Waal HA; Verhoeven-Wind L; Frölich M; Oostdijk W; Wit JM
J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; Di Nero G
J Pediatr; 1993 Jan; 122(1):37-45. PubMed ID: 8419613
[TBL] [Abstract][Full Text] [Related]
18. Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy.
Johansen JS; Jensen SB; Riis BJ; Rasmussen L; Zachmann M; Christiansen C
J Clin Endocrinol Metab; 1990 Jul; 71(1):122-6. PubMed ID: 2370291
[TBL] [Abstract][Full Text] [Related]
19. Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents.
Fors H; Bjarnason R; Wirént L; Albertsson-Wikland K; Bosaeust L; Bengtsson BA; Johannsson G
Clin Endocrinol (Oxf); 2001 Nov; 55(5):617-24. PubMed ID: 11894973
[TBL] [Abstract][Full Text] [Related]
20. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
